A two-year trial of entecavir followed by lamivudine in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24 percent and 12 percent drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint.